The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
To stay abreast of the latest developments at Ananda, we encourage you to follow our social media channels which are:
· Investor Hub: investors.anandadevelopments.com
· Instagram: https://instagram.com/anandadevelopments?igshid=YmMyMTA2M2Y=
Hi DJ and thanks for your question.
It is an interesting point, though I don't think we would look to change names at this point. We would probably have to look at changing our ticker (ANA) as well and probably undergo a wider rebrand which may pull focus and resource from our main aim of executing on the two Phase II clinical trials we have agreed to date, expanding our trial pipeline and securing & building on our relationship with Nottingham Trent Uni on DJT. There is also every chance that a name change could cause more problems than it solves with regards to finding info on the Company as you're effectively starting again from 0.
If we ever do decide to change names though, I am sure
DjWalls
09:37AM 14/12/2023
Appreciate the new hub and looking forward to 2024 very much. Here's to success.
My question, though, is would a name change be in the pipeline at any stage to differentiate us from the Ananda Development out there, as it can get confusing when searching for info. And if so, would you allow shareholder to choose/vote on any new name? Thanks.
Just like to say the Hub looks great and here's to a fantastic 2024 and very much looking forward to up and coming rct news and more collaboration
Share
AQSE:ANA Logo
Ananda Developments
AQSE:ANA
12:01PM 14/12/2023
Thanks Darren! We're happy to hear you like it and looking forward to bringing you lots of exciting things on here in the coming years.
Would be good to hear about an approximate timetable for the trials and an approximate target year for a start to earnings, even if this is 2 to 3 years away.
To the news on all the approaches we have been getting recently though and where that takes us too!
I think the big focus is on the rct's and nhs gateway but just think what would happen if mrx 1 became a licenced medicine and the value creation overnight if that was the case!
It would be good to hear if Ana are receiving any revenue on MRX sales.
Absolutely we have an excellent future ahead.
E-mail landed today so get onboard everybody apart from the crybaby with multiple accounts. Who went from being a normal bloke to a complete headbanger in the space of a few weeks.
Here's to a lively and interesting 2024!
Don't forget to breath you seem stressed lol
How's about a few drops under your tongue sit back and watch this all play out.
. Sleight of hand, smoke and mirrors and get any posts removed that hint at true goings on,normal for a life style company
They are certainly focused and stay dynamic with moving accordingly with how the sector is moving and know who to connect with to ensure the right decisions are made and justified with transparency all the while and I suggest anybody with any direct questions jumps straight into the new hub to get involved
It’s good that Ananda has decided to implement this Investor Hub. Having all information in one place is good to see and it’s accessible for existing and prospective shareholders. I also like the fact that Ananda want to engage, which has never really been an issue.
I’d like to see the question section a bit more obvious but it’s a good start.
Or im just a heavily researched investor that's taken the time to meet the board and visit the facility and was very impressed indeed in what I've seen
That would be my hope. It's not unusual for many companies to have investor hubs and ANA is a little later in the day with it but it's a great central homebase for investors to access everything they need.
It's a super move i say and guess you don't build a hub if you haven't got lots of positive events to communicate in the coming months!
What a super investment opportunity this is!
RNS - Ananda Launches New Interactive Investor Hub
Today 07:00
RNS Number : 6859W
Ananda Developments PLC
14 December 2023
Reach - Non-Regulatory
Ananda Developments plc
("Ananda" or the "Company")
Ananda Developments Launches New Interactive Investor Hub, investors.anandadevelopments.com to provide stakeholders with a more proactive method of communication and enquiry support
Ananda Developments Plc ('Ananda') a company whose ambition is to be a leading provider of cannabinoid-based medicines for the treatment of complex, chronic inflammatory pain conditions is pleased to announce the launch of Ananda's Interactive Investor Hub. For both existing and prospective stakeholders it brings all Ananda's content into a single integrated platform to better inform and engage with investors and stakeholders, including:
regulatory announcements
annual and interim reports
corporate presentations
educational material
Interviews with the company's directors
corporate research on Ananda Developments
Investor Hub also provides an interactive online experience allowing the Company's stakeholders to comment on and ask the Ananda team questions via a portal which will be monitored and responded to promptly. Company RNSs will also still be released via the current regulated services.
To sign up for the Ananda Investor Hub:
1. Visit investors.anandadevelopments.com
2. Follow the prompts to sign up for an investor hub account
3. Complete your account profile
Ananda's CEO, Melissa Sturgess commented: "We have always encouraged our stakeholders to engage with us. We see Investor Hub as an effective platform upon which to further enable our stakeholders including shareholders, potential shareholders and interested parties to interact with Ananda. Investor Hub will also allow us to share more video material, information and insights about our activities and plans. We encourage our shareholders, potential shareholders and wider stakeholders to trial Investor Hub and provide feedback."
Https://twitter.com/exppect/status/1726686503504597414?t=ZLcbSfKNzTcB85YDoc80cw&s=19
That the sound of your stop loss being hit Gazza
From August 2023
MRX: cannabinoid unlicensed medicines
MRX1 has been selected to be used in two Phase 2 RCTs being conducted by leading clinicians from The University of Edinburgh. Drug supply agreements are being finalised and the MRX1 formulation is undergoing stability trials ahead of patient recruitment. Stability trials are being undertaken to align with the test method, outlined in the EU Pharmacopoeia, that will come into force in the EU in July 2024. Ananda expects these methods to apply in the UK at that time. The MRX medicines are being manufactured for the RCTs by a contract manufacturing organisation (CMO), using externally sourced GMP (Good Manufacturing Practice) grade active pharmaceutical ingredients (APIs).